| 2022-GHOS-69724 | |
| Researchers at Purdue University have developed compounds that inhibit SARS-CoV-2 replication and outperform an approved therapy. Pfizer's Paxlovid and Merck's Molnupiravir are the only antiviral drugs available for individuals with severe COVID-19 symptoms. Purdue researchers are designing more potent compounds to address the continued need for effective COVID-19 therapies. The antiviral drugs developed by the Purdue researchers are 3CLprotease inhibitors that potently block SARS-CoV-2 replication. The best of these compounds are more potent than Pfizer's Paxlovid in enzyme inhibition and antiviral assays. The researchers expect the compounds to have drug-like properties. Technology Validation: Enzyme inhibition and antiviral assays Advantages: - Effective inhibition of 3CLpro enzyme - Potent antiviral activity Applications: - COVID-19 treatment |
|
|
|
|
Dec 7, 2022
PCT-Gov. Funding
WO
(None)
(None)
Feb 7, 2022
Provisional-Gov. Funding
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
